

AETIONOMY – Developing a “mechanism based taxonomy” of Alzheimer’s and Parkinson’s Disease


Holger Fröhlich

22 & 23 October 2018 • IMI Scientific Symposium • Brussels, Belgium

AETIONOMY: Vision & Key Challenges

Developing a “mechanism-based” taxonomy of Alzheimer’s and Parkinson’s Disease

- Current classification of neuro-degenerative diseases is purely phenotype based
- Vision: a molecular mechanism based classification
 - Potentially new ways of treating patients
- Project goal: **first proof of principle**



Challenges



innovative
medicine
initiative

- Per disease
- Per study

Scientific Approach

A Truly Collaborative PPP Effort



Knowledge base of candidate disease mechanisms

Data management



Analysis

Patient clustering

Biological validation

Computational validation

Datasets

Existing datasets (clinical + genetic data): discovery

Newly generated

Further existing data (clinical + genetic): validation

Readout / delivery

Potential patient strata and associated mechanisms

Biological markers associated to mechanisms


Validated patient strata



6 partners



AETIONOMY Key Achievements




Large scale inventory of mechanistic hypotheses to map disease landscape

- Interactive, search-able
- Sustainable resource for future data mining activities




Integration and harmonization of ~100 AD + PD studies into one computational and sustainable environment

- 14 EFPIA datasets




Computational methods to validate stratification potential and use for clinical outcome prediction

- AD risk model
- PD diagnosis model
- Genotype based (joint + separate) stratification of Parkinson's and Alzheimer's Disease



Concepts and first proof of concepts for simulating virtual patient cohorts



Experimental validation of disease mechanisms and biomarkers

- New link between mitochondrial dysfunction and neuro-inflammation in PD
- DNA methylation patterns in PD candidate mechanisms
- Validation of >15 neuro-inflammatory protein markers in AD
- Validation of YKL40 as a biomarker for AD

Impact of AETIONOMY

Resources

Inventory of mechanistic hypotheses

Integrated data

Future scientific insights

Computational
Methods and
Tools

Clustering approaches

Prediction models

Virtual cohorts

Experiences and tools
for future projects.

Experiences &
insights

New scientific findings

How to develop a disease taxonomy?

Role model for future
IMI projects.